All In Biotech

Drug Trial Radar · NCT05944926

Improving Outcomes in Depression in Primary Care in a Low Resource Setting

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Mar 18, 2024

Primary completion

Apr 10, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Harvard Medical School (HMS and HSDM)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sangath; All India Institute of Medical Sciences, Bhopal; Vanderbilt University; Brigham and Women's Hospital; Centre for Addiction and Mental Health; Massachusetts General Hospital; Harvard School of Public Health (HSPH); National Institute of Mental Health (NIMH)
First posted
Jul 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The OptimizeD study aims to improve outcomes in depression in primary care in India. This study will randomize 1500 patients with moderate to severe depression to either psychotherapy based on behavioral activation called the Healthy Activity Program (HAP) or antidepressant medication (fluoxetine). The study has two primary objectives: 1. Use patient characteristics to generate a precision treatment rule based on baseline information for predicting in advance what works best for whom (and which patients are unlikely to respond to either treatment and should be referred to specialist care). 2. Conduct a cost-effectiveness analysis by comparing relative costs and effectiveness between those who were randomly allocated to their optimal treatment with those who were randomly allocated to a non-optimal treatment based on the precision treatment rule.

Conditions

  • Depression
  • Depressive Disorder

Interventions

  • Healthy Activity Program (HAP)Behavioral

    HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.

  • Antidepressant medication (fluoxetine)Drug

    Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Depression remissionTime frame: 3 months post recruitment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sangath

    Bhopal, Madhya Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.